lobbying_activities: 1581428

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1581428	bbd97b32-5ae4-430c-8c0b-33bfae5290ab	Q3	CSL BEHRING LLC	308935	CSL BEHRING LLC	2014	third_quarter	HCR	Preserving Access to Orphan Drugs Act (HR 2315/S 1128)- legislation excluding all therapies that solely treat orphan conditions from the annual pharmaceutical fee. Orphan designation - the need to delink clinical superiority from designation Preservation of the Orphan Drug Tax Credit	Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE		170000	0	0	2014-10-01T15:57:12.257000-04:00